The prevalence of systemic lupus erythematosus (SLE) is higher in Asians than Caucasians,
with higher frequency of renal and other major organ manifestations that carry a poorer …

Background: The B-cell activating factor (BAFF) controls the maturation and survival of B
cells. An imbalance in this cytokine has been associated with systemic autoimmunity in SLE …

Systemic lupus erythematosus (SLE) is an autoimmune disease with variable clinical
expression. It is a potentially devastating condition affecting mostly women and leading to …

B cell-activating factor (BAFF) promotes the survival, proliferation and maturation of B
lymphocytes, which are key elements in the pathogenesis of systemic lupus erythematosus …

Juvenile systemic lupus erythematosus (JSLE) is characterised by onset before 18 years of
age and more severe disease phenotype, increased morbidity and mortality compared to …

Introduction: The anti-BAFF monoclonal antibody, belimumab, was approved 5+ years ago
by the US Food and Drug Administration for the treatment of adult SLE patients. Although …

Background Systemic lupus erythematosus (SLE) is the prototype of systemic autoimmune
disease, characterized by loss of immune tolerance against self-antigens where …

Objectives To describe phenotypes and outcomes of extra-renal flares in SLE, to identify
clusters of extra-renal flares based on baseline features, and to develop a machine learning …

Systemic lupus erythematosus (SLE) is a complex systemic autoimmune disease driven by
both innate and adaptive immune cells. African Americans tend to present with more severe …

Objective To assess the relationship between treatment response, baseline biomarker
levels, and atacicept exposure in patients with systemic lupus erythematosus (SLE) in the …